Company: PRME
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001628280-25-018704
Chunk: 0

Company: Prime Medicine, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 0
---
### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### SCHEDULE 14A

#### Proxy Statement Pursuant to Section 14(a) of the

#### Securities Exchange Act of 1934 (Amendment No. )
| Filed by the Registrant |     | ☒ |     | Filed by a Party other than the Registrant |     | ☐ |

Check the appropriate box:

| ☐ |     | Preliminary Proxy Statement                                                     |
| ☐ |     | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☒ |     | Definitive Proxy Statement                                                      |
| ☐ |     | Definitive Additional Materials                                                 |
| ☐ |     | Soliciting Material under §240.14a-12                                           |

#### PRIME MEDICINE, INC.
<div align='center'>(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>

Payment of Filing Fee (Check all boxes that apply):

| ☒ |     | No fee required.                                                                                        |
| ☐ |     | Fee paid previously with preliminary materials.                                                         |
| ☐ |     | Fee computed on table below in exhibit required by Item 25(b) Exchange Act Rules 14a-6(i)(14) and 0-11. |

#### PRIME MEDICINE, INC.

#### 60 First Street

#### Cambridge, MA 02141

#### NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS

#### To Be Held On June 4, 2025
We are pleased to notify you that we will hold the 2025 annual meeting of our stockholders (the “Annual Meeting”) on June 4, 2025, at 2:00 p.m., Eastern Time, in a virtual meeting format, which will be conducted via live webcast. You may attend the Annual Meeting online, vote your shares electronically and submit questions by visiting www.virtualshareholdermeeting.com/PRME2025.

The Annual Meeting will be held for the following purposes:

1. To elect Thomas Cahill, M.D., Ph.D. and Robert Nelsen as Class III Directors, each to serve until the 2028 annual meeting of our stockholders, and until his respective successor shall have been duly elected and qualified, or until his earlier death